Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 Into Phase 1 Multiple-Ascending Dose Cohorts; Topline Study Results Are Expected In Late 2024 Or Early 2025
Portfolio Pulse from Benzinga Newsdesk
Cocrystal Pharma has initiated the multiple-ascending dose phase of its Phase 1 study for CDI-988, an oral pan-viral protease inhibitor targeting viral gastroenteritis and COVID-19. Results are expected by late 2024 or early 2025.
September 26, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cocrystal Pharma has started the multiple-ascending dose phase of its Phase 1 trial for CDI-988, a pan-viral protease inhibitor. This development could impact the stock as it progresses towards potential market approval.
The initiation of Phase 1 trials for CDI-988 is a significant milestone for Cocrystal Pharma, indicating progress in their drug development pipeline. Positive trial results could lead to further clinical phases and potential market approval, which would be beneficial for the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100